Quai.MD’s Post

Private equity investments can drive growth, innovation, and operational improvements in the healthcare sector. In many ways, PE is a response to and an accelerator for vaster health system trends. #privateequity #pe #privateequityinvestments #prvateequitycareers #USPEC

Private equity investments can drive growth, innovation, and operational improvements in the healthcare sector. In many ways, PE is both a response to and an accelerator for vaster health system trends. #privateequity #pe #privateequityinvestments #prvateequitycareers #uspec

In 2024, biotech and health companies have secured approximately $5.6 billion across 110 Series A rounds, representing 53% of all funding at this stage. At elevAID, our RCM and practice management services excel in boosting practice revenue through stringent financial oversight and streamlined operations. With the biotech and health sectors drawing considerable investments, our specialized services are essential for navigating this evolving landscape. Stay ahead of the technological curve with our tailored services designed to optimize your financial outcomes! (source: Crunchbase) #MedicalBilling #PracticeManagement #Investment

Exciting News! Updoc has secured a $20M investment from Bailador Technology Investments!  This boost will help to connect even more Australians with top healthcare practitioners. 🌟 #Updoc #DigitalHealth #InvestmentNews #HealthcareInnovation #AustraliaBusinessNews

Healthcare Industry Trends Investors are cutting smaller checks, deploying capital more slowly and focusing more on diligence. But total fundraising for new health-focused VC and growth funds is down only 14% from 2022 and remains the third highest total over the past decade. The proportion of spoon-fed deals has increased dramatically for all but one healthcare sector since 2021, as investors increasingly use inside and extension rounds to help companies weather a challenging market.

Hello World! Today we're starting Healthcare Investing Simplified, a newsletter about early stage healthcare investing. Want to invest in promising healthcare companies that improve our health and wellbeing but need help understanding the ins and out of investing? You've come to the right place. Our goal is to help you acquire the skills and knowledge necessary to invest with 280+ (and growing!) angel investors at The Healthcare Syndicate and our institutional investor network. Once a week delivered to your inbox, we'll share insights in: - Happenings at the forefront of healthcare through our conversations with early stage companies - How healthcare companies go from 0 to 1 - How to evaluate these early stage companies from an investment perspective. We'll be starting a new series on how to diligence healthcare companies, so I hope you'll join us in our investing journey! Remember, there are no dumb questions, and learning is a lifelong pursuit. Subscribe here: https://lnkd.in/g3GFV9Ev

Private equity firms are showing significant interest in RCM companies, with a surge in activity seen throughout 2023 and into 2024. In 2022 alone, RCM companies were involved in 21 private equity deals, including 18 add-ons and three buyouts. Recent highlights include: > Aquiline Capital Partners Partners' investment in Health Prime International and acquisition of a stake from GPB Capital for US$190 million in 2024. > New Mountain Capital's offer to buy out the remaining ownership of R1 RCM at a staggering US$5.8 billion in 2024. > TA Associates' substantial growth investment in Alpha II - Healthcare RCM, a leading provider of RCM technology solutions to healthcare providers, in 2023. > ECLAT Health Solutions Inc, a portfolio company of Gulf Capital, acquiring the Health Information Management (HIM) division of Excite Health Partners in 2023. > WellSky, a portfolio company of Leonard Green & Partners (LGP) and TPG Capital, expanding its medical coding and RCM offerings with the acquisition of Corridor from HealthEdge Investment Partners in 2023. The question arises: why is this happening, and how will it impact the industry? Find out more in this insightful blog by my colleague Vivek Kumar https://lnkd.in/gQc2FCH5 #RCM #PrivateEquity #HealthcareInvestments #IndustryTrends #EverestGroup #TheHealthcareAnalyst

New Post: Avista Healthcare Partners on the specialist dividend in healthcare - This article, sponsored by Avista Healthcare Partners, discusses the shift from "generalist" to "specialist" approaches in healthcare private equity, emphasizing the need for deep sector expertise to ensure successful investments. David Burgstahler, CEO of Avista, highlights the firm's nearly 30-year history in healthcare, focusing on mid-market product and technology investments, leading to sustainable growth. Avista's strategy involves collaboration with seasoned operating partners and maintaining a narrow focus on six subsectors. The firm prioritizes regulatory compliance and transparency, fostering relationships with regulators to navigate challenges, ultimately achieving significant financial returns through its specialized approach. Read the full article here https://lnkd.in/gX4kPqex #Venturecapital #VC #investment #LP #Limited Partner

Useful. "We’re looking for teams that know how to responsibly grow, with an ability to triage opportunities and allocate resources with due consideration for the cost of capital. That may be for organic growth opportunities or M&A opportunities. Teams that are clear on their mission and the challenge they’re focused on addressing and have demonstrated they can navigate through noise and distractions to do the right things for their primary stakeholders will have the best shot at success. This is healthcare – it’s high stakes and a firm compass on principles is very valuable." The 4PM Ventures team shares this approach as the focus on building platforms is our priority

In the past few weeks, I've talked about the healthcare system challenges because of how out-of-control the structure has gotten. I've mentioned that Myo Impact Company ("MiC") has two sides to its business as a healthcare management company - offering an alternative approach to providing and paying for care, and offering an alternative investment option to average investors. From an investment perspective, MiC opens the opportunity to invest in healthcare (actual healthcare delivery, not just insurance or MedTech companies though we have those wrapped in as well). We have built a private equity fund open to all investors, both "average" and accredited. Whether it's a $200, $2,000, $200,000, or $2M investment, we made it easier too. We use a recognized Alternative Trading System (ATS) for investors to trade MiC shares in our fund without management or carry fees. We trade on Myo Impact Company ("MiC")'s Net Asset Value. Every one of our portfolio companies is selected for it's growth potential as well as its fit in our healthcare ecosystem. The revenue growth of the portfolio companies is reinvested to continually increase the NAV for our investors. Our offering is going retail in a matter of weeks. Follow us now to stay up to date on details. Reach out directly if you'd like to be on our investor list. It's different, but not difficult. It's new but not revolutionary. We've just found a better way to put things together in healthcare and investing to create something that addresses deficiencies in both industries. This is Myo Impact Company ("MiC").